Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Kono, Masamitsu ^a   Hotomi, Muneki ^a   Hollingshead, Susan K ^b   Briles, David E ^b   Yamanaka, Noboru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; PNEUMOCOCCAL SURFACE PROTEIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CHOLERA TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BREAST MILK; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LUNG INFECTION; MATERNAL IMMUNIZATION; MOUSE; NONHUMAN; PLACENTA; PNEUMOCOCCAL INFECTION; PROGENY; SEPSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MICROBIOLOGY; MORTALITY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

MUS; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CHOLERA TOXIN; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80055121247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027102     Document Type: Article

References (79)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. Giebink GS, (2001) The prevention of pneumococcal disease in children. N Engl J Med 345: 1177-1183.
3. Melegaro A, Edmunds WJ, (2004) The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 19: 365-375.
4. Melegaro A, Edmunds WJ, (2004) The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 19: 353-363.
5. Pelton SI, Loughlin AM, Marchant CD, (2004) Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23: 1015-1022.
6. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomized double-blind efficacy study. Lancet 367: 740-748.
7. Black S, France EK, Isaacman D, Bracken L, Lewis E, et al. (2007) Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 771-777.
8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
9. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, et al. (1996) Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 174: 1271-1278.
10. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, et al. (2002) Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185: 927-936.
11. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, et al. (2004) Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 39: 930-938.
12. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
13. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196: 1346-1354.
14. Dagan R, (2009) Serotype replacement in perspective. Vaccine 21 (Suppl 3): C22-24.
15. Mera R, Miller LA, Fritsche TR, Jones RN, (2008) Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 14: 101-107.
16. Hanage WP, (2007) Serotype replacement in invasive pneumococcal disease: where do we go from here? J Infect Dis 196: 1282-1284.
17. Paradiso PR, (2011) Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 52: 1241-1247.
18. Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, et al. (2010) Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 28: 7634-7643.
19. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, et al. (2007) Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196: 1339-1345.
20. Rapola S, Jäntti V, Haikala R, Syrjänen R, Carlone GM, et al. (2000) Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182: 1146-1152.
21. Yamanaka N, Faden H, (1993) Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitis-prone children. J Pediatr 122: 212-218.
22. Hotomi M, Yamanaka N, Saito T, Shimada J, Suzumoto M, et al. (1999) Antibody responses to the outer membrane protein P6 of non-typeable Haemophilus influenzae and pneumococcal capsular polysaccharides in otitis-prone children. Acta Otolaryngol 119: 703-707.
23. Samukawa T, Yamanaka N, Hollingshead S, Murphy TF, Faden H, (2000) Immune response to surface protein A of Streptococcus pneumoniae and to high-molecular-weight outer membrane protein A of Moraxella catarrhalis in children with acute otitis media. J Infect Dis 181: 1842-1845.
24. Virolainen A, Russell W, Crain MJ, Rapola S, Käyhty H, et al. (2000) Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J 19: 134-138.
25. Simell B, Melin M, Lahdenkari M, Briles DE, Hollingshead SK, et al. (2007) Antibodies to pneumococcal surface protein a families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. J Infect Dis 196: 1528-1536.
26. Quiambao BP, Nohynek H, Käyhty H, Ollgren J, Gozum L, et al. (2003) Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 28: 3451-3454.
27. Munoz FM, Englund JA, Cheesman CC, Maccato ML, Pinell PM, et al. (2001) Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 12: 826-837.
28. Briles DE, Hollingshead SK, Brooks-Walter A, Nabors GS, Ferguson L, et al. (2000) The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18: 1707-1711.
29. Briles DE, King JD, Gray MA, McDaniel LS, Swiatlo E, et al. (1996) PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14: 858-867.
30. Briles DE, Tart RC, Swiatlo E, Dillard JP, Smith P, et al. (1998) Pneumococcal diversity: considerations for new vaccine strategies with emphasis on PspA. Clin Micro Review 11: 645-657.
31. Ochs MM, Bartlett W, Briles DE, Hicks B, Jurkuvenas A, et al. (2008) Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog 44: 204-214.
32. Briles DE, Ades E, Paton JP, Sampson JS, Carlone GM, et al. (2000) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68: 796-800.
33. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC, (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68: 3028-33.
34. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, et al. (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182: 1694-1701.
35. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, et al. (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18: 1743-1754.
36. Katsurahara T, Hotomi M, Yamauchi K, Billal DS, Yamanaka N, (2008) Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA). J Infect Chemother 14: 393-398.
37. Hollingshead SK, Becker R, Briles DE, (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68: 5889-5900.
38. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, et al. (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182: 1694-1701.
39. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, et al. (2010) Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 17: 439-446.
40. Miyaji EN, Ferreira DM, Lopes AP, Brandileone MC, Dias WO, et al. (2002) Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun 70: 5086-5090.
41. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, et al. (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18: 1743-1754.
42. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE, (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175: 839-846.
43. Tart RC, McDaniel LS, Ralph BA, Briles DE, (1996) Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 173: 380-386.
44. Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R, (2009) Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect Immun 77: 1613-1622.
45. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, et al. (2008) Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359: 1555-1564 Wilson E, Omer SB, Shahid NS, Breiman RF, Steinhoff MC.
46. Gall SA, (2005) Maternal immunization to protect the mother and neonate. Expert Rev Vaccines 4: 813-818.
47. Glezen WP, Alpers M, (1999) Maternal immunization. Clin Infect Dis 28: 219-224.
48. Daly KA, Toth JA, Giebink GS, (2003) Pneumococcal conjugate vaccines as maternal and infant immunogens: challenges of maternal recruitment. Vaccine 21: 3473-3478.
49. Healy CM, Baker CJ, (2006) Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis 19: 271-276.
50. Quiambao BP, Nohynek H, Käyhty H, Ollgren J, Gozum L, et al. (2003) Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 21: 3451-3454.
51. Kiyono H, Bienenstock J, McGhee JR, Ernst PB, (1992) The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development. Reg Immunol 4: 54-62.
52. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
53. Holmgren J, Czerkinsky C, (2005) Mucosal immunity and vaccines. Nat Med 11; (Suppl): S45-S53.
54. Yamauchi K, Hotomi M, Billal DS, Suzumoto M, Yamanaka N, (2006) Maternal intranasal immunization with outer membrane protein P6 maintains specific antibody level of derived offspring. Vaccine 24: 5294-5299.
55. Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, et al. (2009) Intranasal immunization with mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine 27: 3181-3188.
56. Roberts DM, Guenthert M, Rodewald R, (1990) Isolation and characterization of the Fc receptor from fetal york sac of the rat. J Cell Biol 111: 1867-1876.
57. Simister NE, Rees AR, (1985) Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 15: 733-738.
58. Israel EJ, Patel VK, Taylor S, Marshak-Rothstein A, Semister NE, (1995) Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol 154: 6246-6251.
59. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, et al. (1997) Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92: 69-74.
60. He W, Ladinsky MS, Huey-Tubman KE, Jensen GJ, McIntosh JR, et al. (2008) FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455: 542-546.
61. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, et al. (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104: 903-911.
62. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, et al. (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196: 303-310.
63. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X, (2011) Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29: 158-163.
64. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, et al. (2006) Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 116: 2142-2151.
65. Tuaillon E, Valea D, Becquart P, Al Tabaa Y, Meda N, et al. (2009) Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J Immunol 182: 7155-7162.
66. Arvola M, Gustafsson E, Svensson L, Jansson L, Holmdahl R, et al. (2000) Immunoglobulin-secreting cells of maternal origin can be detected in B cell-deficient mice. Biol Reprod 63: 1817-1824.
67. van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, et al. (2003) Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci USA 100: 14363-14367.
68. Briles DE, Novak L, Hotomi M, van Ginkel FW, King J, (2005) Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73: 6945-6951.
69. Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, et al. (2010) Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol 185: 1755-1762.
70. Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, et al. (2010) Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog 48: 205-213.
71. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN, (2008) Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 15: 499-505.
72. Ferreira DM, Darrieux M, Silvia DA, Leite LC, Ferreira JM, et al. (2009) Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 16: 636-645.
73. Arulanandam BP, Lynch JM, Briles DE, Hollingshead SK, Metzger DW, (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69: 6718-6724.
74. Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, et al. (2007) Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun 75: 5930-5938.
75. Baril L, Briles DE, Crozier P, King JD, Hollingshead SK, et al. (2004) Natural materno-fetal transfer of antibodies to PspA and to PsaA. Clin Exp Immunol 135: 474-477.
76. Simister ME, (2003) Placental transport of immunoglobulin G. Vaccine 21: 3365-3369.
77. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD, (1994) Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1: 667-669.
78. Hashira S, Okitsu-Negishi S, Yoshino K, (2000) Placental transfer of IgG subclasses in a Japanese population. Pediatr Int 42: 337-342.
79. Briles DE, Novak L, Hotomi M, van Ginkel FW, King J, (2005) Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73: 6945-6951.